Ashley A. Baker

Ashley A. Baker

Auto-generated profile, based on publicly available information

Ashley A. Baker

Department of Pediatrics, Division of Hematology Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
SCShanmuganathan Chandrakasan
Shanmuganathan Chandrakasan
MJMichael B. Jordan
Michael B. Jordan
ABAshley Baker
Ashley Baker
EBEdward M. Behrens
Edward M. Behrens
DBDeepika Bhatla
Deepika Bhatla
CACarl E. Allen
Carl E. Allen
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening, hyperinflammatory syndrome. Emapalumab, a fully human monoclonal antibody that neutralizes the proinflammatory cytokine interferon gamma, is approved in the United States to treat primary HLH (pHLH) in patients with refractory, recurrent, or progressive disease, or intolerance with conventional HLH treatments. REAL-HLH, a retrospective study, conducted across 33 US hospitals, evaluated real-world treatment patterns and outcomes in patients treated with ≥1 dose of emapalumab between 20 November 2018 and 31 October 2021. In total, 46 patients met the pHLH classification criteria. Median age at diagnosis was 1.0 year (range, 0.3-21.0). Emapalumab was initiated for treating refractory (19/46), recurrent (14/46), or progressive (7/46) pHLH. At initiation, 15 of 46 patients were in the intensive care unit, and 35 of 46 had received prior HLH-related therapies. Emapalumab treatment resulted in normalization of key laboratory parameters, including chemokine ligand 9 (24/33, 72.7%), ferritin (20/45, 44.4%), fibrinogen (37/38, 97.4%), platelets (39/46, 84.8%), and absolute neutrophil count (40/45, 88.9%). Forty-two (91.3%) patients were considered eligible for transplant. Pretransplant survival was 38 of 42 (90.5%). Thirty-one (73.8%) transplant-eligible patients proceeded to transplant, and 23 of 31 (74.2%) of those who received transplant were alive at the end of the follow-up period. Twelve-month survival probability from emapalumab initiation for the entire cohort (N = 46) was 73.1%. There were no discontinuations because of adverse events. In conclusion, results from the REAL-HLH study, which describes treatment patterns, effectiveness, and outcomes in patients with pHLH treated with emapalumab in real-world settings, are consistent with the emapalumab pivotal phase 2/3 pHLH trial.

24 February 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
DNDavid Noyd
David Noyd
AJAmanda Janitz
Amanda Janitz
ABAshley A. Baker
Ashley A. Baker
WBWilliam H. Beasley
William H. Beasley
NENancy C. Etzold
Nancy C. Etzold
KOKevin C. Oeffinger
Kevin C. Oeffinger
Background: Children with cancer from rural and nonurban areas face unique challenges. Health equity for this population requires attention to geographic disparities in optimal survivorship-focused care. Methods: The Oklahoma Childhood Cancer Survivor Cohort was based on all patients reported to the institutional cancer registry and ≤ 18 years old at diagnosis between January 1, 2005, and September 24, 2014. Suboptimal follow-up was defined as no completed oncology-related clinic visit five to 7 years after their initial diagnosis (survivors were 7–25 years old at end of the follow-up period). The primary predictor of interest was rurality. Results: Ninety-four (21%) of the 449 eligible survivors received suboptimal follow-up. There were significant differences (P = 0.01) as 36% of survivors from large towns (n = 28/78) compared with 21% (n = 20/95) and 17% (n = 46/276) of survivors from small town/isolated rural and urban areas received suboptimal follow-up, respectively. Forty-five percent of adolescents at diagnosis were not seen in the clinic compared with 17% of non-adolescents (P < 0.01). An adjusted risk ratio of 2.2 (95% confidence interval, 1.5, 3.2) was observed for suboptimal follow-up among survivors from large towns, compared with survivors from urban areas. Seventy-three percent of survivors (n = 271/369) had a documented survivorship care plan with similar trends by rurality. Conclusions: Survivors from large towns and those who were adolescents at the time of diagnosis were more likely to receive suboptimal follow-up care compared with survivors from urban areas and those diagnosed younger than thirteen. Impact: Observed geographic disparities in survivorship care will inform interventions to promote equitable care for survivors from nonurban areas.

13 November 2021 in Cell Biology and Toxicology
Verified
Journal Article
Closed access
PDF file
DJDrishti Jain
Drishti Jain
DSDinesh Babu Somasundaram
Dinesh Babu Somasundaram
SASheeja Aravindan
Sheeja Aravindan
ZYZhongxin Yu
Zhongxin Yu
ABAshley Baker
Ashley Baker
Natarajan AravindanNatarajan Aravindan
Natarajan Aravindan

1 July 2021 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
CIChibuzo Ilonze
Chibuzo Ilonze
KGKari M. Galipp
Kari M. Galipp
TSTeresa Scordino
Teresa Scordino
WMWilliam H. Meyer
William H. Meyer
ABAshley Baker
Ashley Baker
Cyclic neutropenia has been rarely associated with chronic inflammation and development of reactive AA amyloidosis. We report a family with cyclic neutropenia with associated renal and thyroid amyloid. A 12-year-old female presented with thyromegaly, recurrent aphthous ulcers, severe neutropenia, and renal failure. Renal and thyroid biopsies revealed abundant amyloid deposition. Presence of a heterozygous ELANE c.358 A>T gene mutation p.I120F variant with autosomal dominant inheritance confirmed the diagnosis of cyclic neutropenia. The patient’s father also had neutropenia and amyloidosis with renal failure. We started filgrastim to attenuate neutropenia and thereby reduce chronic inflammation and minimize further amyloid deposition.

1 May 2023
Verified
Other
Open access
PDF file
DNDavid Noyd
David Noyd
AJAmanda Janitz
Amanda Janitz
ABAshley A. Baker
Ashley A. Baker
WBWilliam H. Beasley
William H. Beasley
NENancy C. Etzold
Nancy C. Etzold
KOKevin C. Oeffinger
Kevin C. Oeffinger
Rural-Urban Commuting Area (RUCA) codes, definitions, and categories (adapted from https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/ and https://depts.washington.edu/uwruca/ruca-uses.php)

1 May 2023
Verified
Other
Open access
PDF file
DNDavid Noyd
David Noyd
AJAmanda Janitz
Amanda Janitz
ABAshley A. Baker
Ashley A. Baker
WBWilliam H. Beasley
William H. Beasley
NENancy C. Etzold
Nancy C. Etzold
KOKevin C. Oeffinger
Kevin C. Oeffinger
Geographic distribution of survivors with Passport for Care